Mucus-penetrating nonviral gene vaccine processed in the epithelium for inducing advanced vaginal mucosal immune responses

• DOI: 10.1016/j.apsb.2022.11.004
• Publication Date: 2022-11-04T18:01:03Z
• Authors: Qunjie Bi; Xu Song; Yangyang Zhao; Xueyi Hu; Huan Yang; Rongrong Jin; Yu Nie
• Keywords: Nanocarriers; Mucosal Immunity

Establishment of vaginal immune defenses at the mucosal interface layer through gene vaccines promise to prevent infectious diseases among females. Mucosal barriers composed a flowing mucus hydrogel and tightly conjugated epithelial cells (ECs), which represent main technical difficulties for vaccine development, reside in harsh, acidic human environment. Different from frequently employed viral vectors, two types nonviral nanocarriers were designed concurrently overcome induce responses. Differing design concepts include charge-reversal property (DRLS) mimic virus that uses any as factories, well addition hyaluronic acid coating (HA/RLS) directly target dendritic (DCs). With suitable size electrostatic neutrality, these nanoparticles penetrate with similar diffusivity. The DRLS system expressed higher level carried papillomavirus type 16 L1 compared HA/RLS vivo. Therefore it induced more robust mucosal, cellular, humoral Moreover, DLRS applied intravaginal immunization high IgA levels intramuscularly injected DNA (naked), indicating timely protection against pathogens layer. These findings also offer important approaches fabrication other systems.